Our leadership team has experience throughout the drug development process, from drug discovery through to commercialization
Chief Executive Officer
Robert W. Duggan joined the Board of Directors in December 2019 and has been the Executive Chairman of our Board since February 2020. Mr. Duggan has served as our Chief Executive Officer since April 2020.
Since 2015, Mr. Duggan has also been the Founder and CEO of Duggan Investments, a venture capital and equity investment firm. His firm’s investments primarily focus on patient-friendly breakthrough solutions to complex diseases that extend patients’ lives.
From 2008 to 2015, Mr. Duggan was Chairman, CEO, and the largest investor in Pharmacyclics, Inc., a patient-friendly, science-based, employee-driven developer of small-molecule medicines for the treatment of certain cancers. Mr. Duggan led both the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Johnson & Johnson in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie for approximately $21B remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
From 1990 to 2003, Mr. Duggan was Chairman of the Board of Directors of Computer Motion, Inc., a groundbreaking robotic surgery company that helped change the way in which many surgical procedures are performed around the world with the assistance of its minimally invasive, robotics-based surgical systems. From 1997 to 2003, Mr. Duggan also served as CEO of Computer Motion. In June 2003, Computer Motion merged with Intuitive Surgical, Inc. From the completion of the merger in 2003 until 2011, Mr. Duggan served on the Board of Directors of Intuitive Surgical.
Mr. Duggan received a US Congressional Medal of Merit from Congressman Dr. Ron Paul in 1985. In 2000, he was named a Knight of the Legion D’Honor by President Jacques Chirac of France.
Beyond Summit, Mr. Duggan is currently the Chairman of the Board at Pulse BioSciences, Inc., and is also a member of the University of California at Santa Barbara Foundation Board of Trustees. Mr. Duggan has also funded two Chairs in Mathematical, Life, and Physical Sciences, as well as a Chair in Religious Studies at the University of California at Santa Barbara.
Chief Operating Officer
Maky Zanganeh, DDS, has served as Summit’s Chief Operating Officer and has been a member of the Board of Directors since November 2020.
She has more than 15 years of management, corporate, clinical, and business experience in the pharmaceutical, medical device, and technology industries.
Most recently, Dr. Zanganeh is the Founder & CEO of Maky Zanganeh and Associates (“MZA”), which provides consulting services to businesses in product development, research, and transactions.
Prior to starting and leading MZA, Dr. Zanganeh held multiple leadership positions at Pharmacyclics, Inc., from 2008 to 2015, culminating in her role as Chief Operating Officer, where she oversaw all clinical, research, commercial, and business-related matters. Dr. Zanganeh played a key role both in the multimillion-dollar collaboration and license deal for ibrutinib (later marketed as IMBRUVICA®) with Janssen Biotech, Inc. in 2011, and the subsequent sale of Pharmacyclics to AbbVie Inc. in 2015. The acquisition of Pharmacyclics by AbbVie remains one of the largest transactions to have occurred in the pharmaceutical and biotechnology industries.
Previously, she held senior positions of increasing responsibility within companies such as Robert Duggan & Associates, a private investment firm, and Computer Motion, Inc., a pioneer in robotic surgery.
Dr. Zanganeh earned FierceBiotech’s “Top Women in Biotech” award in 2013. She received her DDS from Louis Pasteur University (France) and her MBA from Schiller International University (France).
Beyond Summit, Dr. Zanganeh is currently a board member for Pulse BioSciences, Inc. and RenovoRx, Inc.
Chief Scientific Officer
Dave Powell, PhD, joined Summit from GSK where he served as Director and Head of the Crick-GSK Biomedical LinkLabs, based at GSK’s UK R&D hub at Stevenage, UK, and The Francis Crick Institute in London.
Dr. Powell held a number of positions of increasing seniority in his time at GSK. As part of his work there, he participated in antibiotic discovery, assay development, high throughput screening design and implementation, and lead optimisation support. In his most recent role at GSK, he led a collaboration with the Crick Institute, in addition to providing support to GSK’s ‘Discovery Partnerships with Academia’ team which collaborated with academic groups in downstream drug discovery.
Dr. Powell was awarded a BSc and MSc from the National University of Ireland Galway, before completing a PhD in biochemistry at Cardiff University (UK).
Head of Business Development
Head of Information Technology
Will Black is our Head of IT responsible for all IT infrastructure, systems, and processes at Summit. He is also responsible for Computer System Validation and works closely with all business departments and Quality Assurance to ensure that Summit’s GxP systems meet FDA and EMA criteria.
Mr. Black was previously at Iovance Biotherapeutics where his most recent project was designing IT systems and infrastructure for the largest US GMP cell and tissue therapy manufacturing facility. Prior to that he spent 8 years at Pharmacyclics leading IT and supporting R&D where he was the principal SME for all IT inspections and audits.
Mr. Black received his BSc from Napier University (UK) and has worked professionally in the UK, the Middle East, and the US for the last 30 years.
Head of Research, Oncology & Inflammation
Betty Y. Chang, PhD, is our Head of Research, leading efforts for discovering new molecules for our growing pipeline.
Prior to Summit, Dr. Chang was Senior Vice President of Translational Research and Early Development, part of the executive team, of Molecular Templates, an immunotoxin company where she was responsible for pharmacology, toxicology, and clinical PK/PD functions. From 2018-2019, she was Chief Operating Officer & Executive Vice President of Product Development at Angarus Therapeutics, an early-stage start-up. From 2009-2018, she was at Pharmacyclics (acquired by AbbVie in 2015) where she was ultimately the Head & Vice President of Research. In that function, she built and led the strategy and operations of a team responsible for drug discovery, pharmacology, translational medicine, and early development activities for IMBRUVICA® (ibrutinib). Dr. Chang started her career at Cell Genesys, a gene / cell therapy company in 1999, and then was an Associate Director at Rigel and Alder Biopharmaceuticals with increasing responsibilities in research and development.
Dr. Chang has published over 100 research manuscripts, conference abstracts, and patent publications. Dr. Chang received her Ph.D. degree in Biochemistry and Molecular Biology from the University of California, Davis, and completed her postdoctoral fellowship in cancer biology at Stanford School of Medicine.
Head of Biometrics
Fong Clow, D.Sc., is our Head of Biostatistics, Data Management, and Statistical Programming. She provides strategic leadership and analysis to the product development cycle.
Dr. Clow brings over 30 years of experience leading extensive teams in biometrics and drug development. She joined us from Pharmacyclics, an AbbVie company, where she was the SVP of Biostatistics, Statistical Programming, and Clinical Data Management. Prior to AbbVie, Dr. Clow held leadership roles at Genentech and several biotech companies. Dr. Clow has had 14 successful NDA / BLA submissions and approvals, including 11 in oncology for IMBRUVICA® (ibrutinib). She has received multiple awards for her accomplishments and contributions, including the 2019 Lagakos Distinguished Alumni Award from Harvard T.H. Chan School of Public Health.
Dr. Clow received her Doctor of Science and Master of Science degrees from Harvard School of Public Health.
Head of Investor Relations & Corporate Strategy
Dave Gancarz, CPA, is our Head of Investor Relations and Corporate Strategy, who provides strategic leadership and communication on our company’s corporate affairs, strategy, and endeavors to our various stakeholders. Mr. Gancarz’s previous experience focused on commercial finance, general corporate finance, and public accounting.
Mr. Gancarz joined Summit from Athenahealth, Inc., where he most recently led the commercial finance team, where he oversaw the company’s overall pricing strategy, deal pricing, deal administration, and sales operations functions. Prior to that, he held leadership positions in accounting at Athenahealth. Mr. Gancarz began his career at PricewaterhouseCoopers, where he was a Senior Manager in the Boston, MA and Miami, FL offices.
Mr. Gancarz received his MSA and BSBA degrees from Stonehill College and is a Certified Public Accountant in Massachusetts and Florida.
Head of Clinical Affairs
Camilla S. Graham, MD, is our Head of Clinical Affairs who provides strategic leadership and communication on our key priority assets and product value. An infectious disease specialist, she has practiced since 2001 at Beth Israel Deaconess Medical Center and is on faculty at Harvard Medical School in Boston, MA.
Additionally, Dr. Graham has 14 years of experience straddling academic medicine and the pharmaceutical industry, including leading the launch of INCIVEK® (telaprevir) and KALYDECO® (ivacaftor) as the Global Head of Medical Affairs at Vertex Pharmaceuticals, and advising numerous state and federal government agencies on access to medications on the academic side.
Dr. Graham received her MD from Medical College of Pennsylvania and her MPH from Harvard School of Public Health.
Head of Human Resources
Campbell Hair is our Head of Human Resources, and is an HR leader with over 30 years of experience. Most recently, Mr. Hair was the CHRO at Ciklum. Ciklum was an international software development and IT outsourcing company. It was headquartered in London but with software development centres primarily based in Ukraine and other Eastern European countries.
Prior to Ciklum, Mr. Hair was CHRO for Xchanging in the UK, which grew from five hundred employees in the UK to over eight thousand employees in over fifteen countries across South East Asia, North America and Europe. Mr. Hair’s early career began at Ford Motor Company, where he undertook a number of different HR roles including in Manufacturing, Product Development, Sales, and IT working across Europe and the US.
Mr. Hair has a Master of Law (LLM) degree in European Employment Law and a BSc in Business Studies from Leicester University (UK).
Head of Regulatory Affairs
Erik Poulsen is Head of Regulatory Affairs at Summit. He is responsible for providing guidance across functions to ensure that global regulatory strategies are in place to provide the best outcome for patients and healthcare professionals.
Mr. Poulsen has over 25 years of experience in the industry providing leadership in gaining global approval for multiple products across multiple therapeutic areas. Before joining Summit, Mr. Poulsen led filings that achieved regulatory approval, at Kite Pharma, Pharmacyclics, Janssen, and Amgen.
Mr. Poulsen received his MS in Biostatistics at UCLA.
Shelley D Spray
Head of Marketing
Head of Clinical Pharmacology & DMPK
Juthamas Sukbuntherng, PhD, is our Head of Clinical Pharmacology and DMPK who provides strategic leadership on preclinical and clinical development of our assets and pipelines. She has been involved in early and late development of multiple approved drugs, such as SUTENT® (sunitinib malate), HORIZANT® (gabapentin enacarbil) and IMBRUVICA® (ibrutinib).
Dr. Sukbuntherng has nearly 25 years of experience in drug development from discovery to clinical in biotechnology and pharmaceutical industry. In her latest role at Pharmacyclics, an AbbVie company, she successfully provided clinical pharmacology and DMPK support to the US and global approval of IMBRUVICA® (ibrutinib) for the treatment of several oncology indications. In addition, she provided scientific leadership to cross-functional teams and led several discovery projects.
Dr. Sukbuntherng received her PhD in Pharmacokinetics from the University of Arizona.
Head of Clinical Operations
Deepali Suri is Head of Clinical Operations and Project Management at Summit. Ms. Suri is a Clinical Development Leader recognized for strategic development and implementation of global clinical programs in multiple therapeutic indications.
Ms. Suri has experience spanning 20 years leading high performance operations teams in delivery of complex clinical trials. Prior to joining Summit, Ms. Suri was Head of Clinical Operations, Clinical Data Management, and Clinical Drug Supply Operations at Sunesis Inc. Prior to Sunesis, Ms. Suri was an Executive Director at Pharmacyclics, leading Clinical Operations and execution of IMBRUVICA® (ibrutinib) trials. Ms. Suri led multiple studies and study teams in Phase II-III Imbruvica® programs from startup through regulatory approvals in CLL, SLL, MZL, and Solid Tumors to ensure that the study deliverables were achieved per the set milestones. Ms. Suri was Recipient of AbbVie’s highest honor, the Chairman’s Award, for exemplary leadership on Imbruvica® Phase III CLL program.
Ms. Suri received her Master’s degree in Pharmacology from University of Delhi (India).
Head of CMC & Supply Chain
Laura Trespidi, PhD, is our Head of CMC and Supply Chain, who provides strategic leadership for all CMC product development activities and end-to-end Supply Chain and Technical Operations functions. Dr. Trespidi has over 28 years’ experience in product development and external manufacturing across several dosage forms, therapeutic areas, and team leadership.
Additionally, Dr. Trespidi has led global CMC and External Manufacturing teams through all stages of product lifecycle at Mundipharma, Shire Pharmaceutical, and GSK. She is recognized for her Extensive knowledge of global regulation and guidelines that impact the chemistry and manufacturing of pharmaceutical products. She led interactions with global RA Agencies and attended more than 20 international quality audits. She is a Subject Matter Expert (SME) for technical due diligences. She led multidisciplinary Late and Early Development Product Strategy teams. Dr. Trespidi is a pioneer of the external development and manufacturing model and an expert in outsourcing CMC activities and commercial manufacturing.
Dr. Trespidi holds a PhD in Pharmaceutics from the School of Pharmacy, University of Milan (Italy).
Head of Patient Safety & Pharmacovigilance; Head of Quality Assurance
Deepa Venkataraman is our Head of Global Patient Safety and Pharmacovigilance and our Head of Quality Assurance, who provides global strategic, scientific, and operational leadership. She comes with extensive experience in Patient Safety, Clinical Development, Research, Quality, and strategic leadership spanning over 18 years. Her most recent role was at AbbVie as the Head of Global Case Management, Global Medical Coding, and Medical Safety Review organization. She had built a highly talented Pharmacovigilance function from ground up at Pharmacyclics (acquired by AbbVie in 2015), led the team through 11 approvals for IMBRUVICA® (ibrutinib) for over 7 years, grew the team 50-fold, and led the successful integration with AbbVie in 2019. Prior to Pharmacyclics, Ms. Venkataraman was at Johnson & Johnson, where she contributed towards successful launch of INCIVO® (telaprevir), ZYTIGA® (abiraterone acetate), INVOKANA® (canagliflozin), and NUCYNTA® (tapentadol).
Through her innovative work, Ms. Venkataraman has received several awards and was nominated in 2019 for FiercePharma’s “50 Fiercest Women in Life Sciences” award. She is an active and passionate public speaker at various high-profile Safety and Women’s leadership congresses.
Ms. Venkataraman received her Master’s Degree in Pharmacy with specialization in Medical Chemistry from Rajiv Gandhi University (India).